Immunohistochemical evaluation of thymidylate synthase in gastric carcinoma using a new polyclonal antibody
- 1 October 1998
- Vol. 83 (7) , 1300-1306
- https://doi.org/10.1002/(sici)1097-0142(19981001)83:7<1300::aid-cncr5>3.0.co;2-m
Abstract
Before this study was conducted, the clinical and therapeutic significance of immunohistochemical evaluation of thymidylate synthase (TS) in patients with gastric carcinoma had not yet been clarified. TS was immunohistochemically evaluated in 134 gastric carcinomas using anti-TS antibody. TS expression, 11 clinicopathologic variables, and survival were studied, and the correlations among them were investigated. The groups with high and low TS levels consisted of 56 and 78 patients, respectively. Granular cytoplasmic staining patterns of tumor cells were produced by immunohistochemical staining of the gastric carcinoma tissues. The grade of TS staining was significantly correlated with three clinicopathologic variables: depth of invasion, peritoneal metastasis, and stage of the carcinoma (P < 0.05). A univariate analysis revealed that the 5-year survival was significantly better for the low TS group than for the high TS group (P < 0.05): 65.2% for the low TS group and 43.2% for the high TS group. The group with high grade TS staining who received chemotherapy because of the advanced stage of their disease had worse prognoses even if they received adjuvant chemotherapy. A multivariate analysis revealed that four variables (peritoneal metastasis, lymphatic invasion, liver metastasis, and TS staining grade) independently contributed to survival (P < 0.05). The hazard ratio for the group with low grade TS staining was 0.464 compared with the group with high grade staining. The immunohistochemical evaluation of TS using this anti-TS antibody may be clinically and therapeutically useful in determining the prognosis of gastric carcinoma patients. Cancer 1998;83:1300-1306. © 1998 American Cancer Society.Keywords
This publication has 18 references indexed in Scilit:
- A new prognostic factor for colorectal carcinoma, thymidylate synthase, and its therapeutic significanceCancer, 1998
- Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival.Journal of Clinical Oncology, 1996
- ‘Tomudex’ (ZD1694): Results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopeniaEuropean Journal Of Cancer, 1995
- Quantitation of intratumoral thymidylate synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: Preliminary report from an ongoing trialEuropean Journal Of Cancer, 1995
- ZD1694 (Tomudex): A new thymidylate synthase inhibitor with activity in colorectal cancerEuropean Journal Of Cancer, 1995
- Thymidylate synthase and drug resistanceEuropean Journal Of Cancer, 1995
- Antigen retrieval immunohistochemistry under the influence of pH using monoclonal antibodies.Journal of Histochemistry & Cytochemistry, 1995
- Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: An index of cell proliferation with evidence of deregulated expression in some, neoplasmsThe Journal of Pathology, 1990
- Fluorouracil: biochemistry and pharmacology.Journal of Clinical Oncology, 1988
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958